



ASX ANNOUNCEMENT

30 May 2025

CARDIEX COMPLETES INSTITUTIONAL PLACEMENT AND LAUNCHES FULLY UNDERWRITTEN ENTITLEMENT OFFER

Not for release to US wire services or distribution in the United States

Highlights:

- Firm commitments received to raise \$2.4 million through a Share Placement to institutional and sophisticated investors.
- Launch of fully underwritten, non-renounceable Entitlement Offer to existing eligible shareholders to raise up to approximately \$4.1 million on the same terms as the Share Placement.
- C2 Ventures Pty Ltd (a Company jointly owned by Directors Niall Cairns and Craig Cooper) has committed:
 - \$0.736 million to the Share Placement (pro rata to their existing holding), subject to shareholder approval at an extraordinary meeting expected to be held in July 2025.
 - To fully take up their \$1.2 million entitlement under the Entitlement Offer.
 - To sub-underwrite the Entitlement Offer in part, subject to compliance with the regulatory requirements.
- Funds raised will largely support new device manufacturing, marketing and sales activities, and commercial scale-up of the CONNEQT Pulse.

Cardiex Limited (ASX: CDX) (**Cardiex**, the **Company**) is pleased to announce it has secured firm commitments to raise \$2.4 million (before costs) through a Share Placement of new fully paid ordinary shares ("**Shares**") to institutional and sophisticated investors (the "**Share Placement**").

Following the Share Placement, the Company will undertake a 1-for-4 non-renounceable pro-rata Entitlement Offer ("**Entitlement Offer**") to eligible shareholders (defined below) to raise up to a further approximately \$4.1 million (before costs) on the same terms as the Share Placement (together referred to as the "**Offer**").

New Shares issued under the Offer will be issued at \$0.04 per Share ("**Offer Price**").

Cardiex CEO, Craig Cooper, commented:

"This capital raise is a pivotal step in our journey to scale CONNEQT Health into a category leader in arterial health solutions. With strong support from new and existing shareholders, including C2 Ventures, we're now well-positioned to accelerate our commercial rollout, expand our supply chain and deliver on our vision to make arterial health monitoring accessible to millions."

For personal use only



Joint Lead Managers

Blackpeak Capital, Stralis Capital Partners and Taylor Collison have been appointed as Joint Lead Managers to the Offer. Blackpeak Capital has been appointed underwriter to the Entitlement Offer.

Share Placement

The Share Placement will consist of the issue of approximately 60.9 million new Shares at an Offer Price of \$0.04 to raise \$2.4 million (before costs).

C2 Ventures has committed to subscribe for a total of approximately 18.4 million new Shares, subject to shareholder approval at the General Meeting (representing a Placement subscription amount of approximately \$0.736 million).

The Company will issue 42,500,000 shares under the Company's ASX Listing Rule 7.1 capacity.

Entitlement Offer

In addition to the Share Placement, the Company is also undertaking a fully underwritten non-renounceable pro-rata Entitlement Offer on the basis of 1 new Share for every 4 existing Shares held by eligible shareholders on the record date, at an Offer Price of \$0.04 per new Share. The Entitlement Offer will raise approximately \$4.1 million via the issue of approximately 101.5 million new Shares at the Offer Price.

The Entitlement Offer is available to all shareholders registered at 7:00pm (AEST) on Wednesday, 4 June 2025 ("**Record Date**") who have a registered address in Australia, New Zealand, Singapore, Hong Kong or the United Kingdom as noted on the Company's share register or are a shareholder that the Company has otherwise determined is eligible to participate in the Entitlement Offer ("**Eligible Shareholders**").

Eligible Shareholders who take up their full entitlement may also apply for additional Shares in excess of their entitlements, which are not subscribed for by other ineligible and eligible shareholders pursuant to the Entitlement Offer ("**Top Up Facility**"), on the same terms as the Offer.

C2 Ventures has committed to take up its full pro rata entitlement under the Entitlement Offer, totalling approximately \$1.2 million and will also sub-underwrite the Entitlement Offer up to \$1.2 million of the fully underwritten shortfall, subject to compliance with the ASX Listing Rules and the Corporations Act.

Use of Funds

Funds raised will primarily be applied towards new device manufacturing, marketing and sales activities, and for commercial expansion. Full details of the Company's intended use of funds are set out in the Investor Presentation which accompanies this announcement.

Investor Webinar

Cardiex will host an investor webinar to provide an update on recent company developments and to share insights into the Company's strategic roadmap and commercial rollout of CONNEQT Health.

Details of the webinar will be announced in the coming days.

For personal use only

Indicative Timetable

Event	Date
Trading Halt Lifted and Cardix announces Share Placement and Entitlement Offer Lodgement of Entitlement Offer Cleansing Notice	Friday, 30 May 2025
Ex date for Entitlement Offer (7.00pm, AEST)	Tuesday, 3 June 2025
Record Date for the Entitlement Offer	Wednesday, 4 June 2025
Settlement of Share Placement via DvP	Wednesday, 4 June 2025
Allotment of Share Placement	Thursday, 5 June 2025
Entitlement Offer & Top-up Facility Opens	Friday, 6 June 2025
Despatch of Entitlement Offer Documents to Shareholders	Friday, 6 June 2025
Entitlement Offer & Top-up Facility Closes	Friday, 20 June 2025
Trading in new securities commences on a deferred settlement basis	Monday, 23 June 2025
Announce results of the Entitlement Offer & Top-up Facility, and Shortfall	Tuesday, 24 June 2025
Settlement of Entitlement Shortfall via DvP	Thursday, 26 June 2025
Allotment of Entitlement Offer & Top-up Facility shares, and Shortfall	Friday, 27 June 2025
EGM to approve C2 Ventures Placement Allocation	July 2025
Settlement of C2 Ventures Placement Allocation	July 2025
Allotment of C2 Ventures Placement Allocations	July 2025

The above dates are indicative only and may change without notice. The Joint Lead Managers and the Company reserve the right to vary any and all of the above dates without notice, subject to the Corporations Act, Listing Rules and other applicable laws. In particular, the Company reserves the right to vary the opening date of any offer and the closing date of any offer without prior notice, which may have a consequential effect on the other dates. The Company also reserves the right not to proceed with the offers at any time before the issue of new Shares. The Entitlement Shortfall Offer may close at such earlier date as the Directors, in their absolute discretion, determine.

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -



For more information, please contact:

Investor Relations
Rod Hinchcliffe
rod.hinchcliffe@mcpartners.com.au

Media Relations
Melissa Hamilton
melissa.hamilton@mcpartners.com.au

About Cardiex

Cardiex's mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market leading SphygmoCor[®] vascular biomarker technology. Cardiex is listed on the Australian Stock Exchange ("ASX:CDX").

Important Notice

Not for distribution or release in the United States

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States or any other jurisdiction in which such an offer would be illegal. Any securities described in this announcement have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended ("**US Securities Act**") or the securities laws of any other state or other jurisdiction of the United States. Accordingly, the securities described in this announcement may not be offered or sold, directly or indirectly, in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable laws of any state or other jurisdiction of the United States.

Forward-Looking Statements

This announcement contains certain contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this announcement are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of Cardiex, its directors and management. This includes statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of Cardiex's business strategies. The success of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or

For personal use only



regulation, none of Cardiex, its representatives or advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this announcement. The forward-looking statements are based on information available to Cardiex as at the date of this announcement. Except as required by law or regulation (including the Listing Rules), none of Cardiex, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

For personal use only